Recent Investment Analysts’ Ratings Updates for Immunovant (IMVT)

A number of research firms have changed their ratings and price targets for Immunovant (NASDAQ: IMVT):

• 5/26/2026 – Immunovant had its price target raised by Guggenheim from $44.00 to $62.00. They now have a “buy” rating on the stock.
• 5/22/2026 – Immunovant had its price target raised by Truist Financial Corporation from $23.00 to $30.00. They now have a “hold” rating on the stock.
• 5/21/2026 – Immunovant had its “buy” rating reaffirmed by Citigroup Inc..
• 5/21/2026 – Immunovant had its price target raised by HC Wainwright from $35.00 to $40.00. They now have a “buy” rating on the stock.
• 5/21/2026 – Immunovant had its price target raised by Bank of America Corporation from $32.00 to $43.00. They now have a “buy” rating on the stock.
• 4/15/2026 – Immunovant had its price target raised by The Goldman Sachs Group, Inc. from $29.00 to $32.00. They now have a “neutral” rating on the stock.
• 4/8/2026 – Immunovant had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Activity

In other news, Director Andrew J. Fromkin sold 221,951 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $33.51, for a total transaction of $7,437,578.01. Following the completion of the transaction, the director directly owned 74,382 shares in the company, valued at approximately $2,492,540.82. The trade was a 74.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Tiago Girao sold 25,760 shares of the business’s stock in a transaction dated Thursday, April 23rd. The stock was sold at an average price of $29.62, for a total value of $763,011.20. Following the transaction, the chief financial officer owned 247,596 shares of the company’s stock, valued at $7,333,793.52. The trade was a 9.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 300,092 shares of company stock worth $9,553,291. Corporate insiders own 1.80% of the company’s stock.

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.